ENDO 2022, Georgia, United States Of America, 11 - 14 June 2022, pp.1-4
The cause-effect relationships of dysbiosis andtype 2 diabetes are complex and remain to beelucidated. The aim of the study was to evaluateintestinal microbiota composition in patients withtype 2 diabetes. The primary endpoint was thechange from baseline in intestinal microbiotacompositon after 12 weeks of treatment andcomparison with healthy controls. During thestudy period, 24 diabetic patients and 10 age-matched healthy controls were planned to enrollthe study. At the first visit (before treatment), atphylum level, Bacteroidetes abundance havebeen observed in diabetic group, whileActinobacteria and Firmicutes in healthy controls. After 12 weeks of treatment (receiving oralantidiabetic treatment, metformin or linagliptin),at genera level, Lactobacillus, Rothia andCollinsella increased in type 2 diabetes grouphowever, microbiota composition was stilldifferent compared to the healthy controls. Wereport that there is a substantial change in thecomposition of the gut microbiota in patients with type 2 diabetes. We observed the beneficialeffects as relative abundance of short chain fattyacid producing bacteria increased in metformingroup. Further studies will highlight theinteraction of the anti-diabetic drugs with gutmicrobiota composition.